CYP3A4*1B and CYP3A5*3 Single Nucleotide Polymorphisms in Iranian Bladder Cancer Patients

The environmental procarcinogen which are responcible for carcinogenesis, to form the proximate carcinogen, they require metabolic activation by drug metabolizing enzymes. The CYP3A subfamily enzymes play an important role in elimination of drugs. The substrates for CYP3A4 enzyme include drugs, and endogenous substances. Therefore, allelic changes in the coding regions of CYP3A4, increases the risk of developing cancers. CYP3A5 is expressed polymorphically in human liver, but consistently in lung, colon, and kidney.The purpose of this study was to analysis the frequency of alteration in CYP3A4 and CYP3A5 genes and to determine the role of their polymorphisms in bladder cancer patients. For this reason, 113 patients with bladder cancer and same number of healthy people as control were collected from Hashemi Nezhad Hospital, Tehran, Iran. DNA was extracted and investigated by PCR-RFLP method. Data analysis was performed using SPSS software (version 19). The results indicated that there was no significant association between CYP3A4*1B gene polymorphism and bladder cancer risk (OR=1.83, 95% CI=0.97-3.46, P=0.062). Also no association was found with individuals carrying the *3 genotype of CYP3A5 gene with bladder cancer in this study among studied population (OR=1. 28; 95% CI=0.68-2.41, P=0.42). No association was found between genotypes and grade and stage of disease with bladder cancer.